Tag: NASD:EDSA

Following the announcement of a significant private placement transaction, Edesa Biotech, Inc. (NASDAQ: EDSA) stock saw a significant increase. EDSA shares had increased by an astounding 112.90% to a trading price of $3.96 as of the most recent market check. The positive market reaction highlights investor confidence in the company’s strategic financial move.

Details of the Private Placement Transaction

Edesa Biotech said that it has completed a successful private placement, issuing 3,468,746 common shares and 834 newly designated Series B-1 convertible preferred shares. $10,000 for each preferred share and $1.92 for each ordinary share were the prices of the at-the-market transaction, which was carried out in accordance with Nasdaq standards. Notably, EDSA’s officers and directors contributed a total of almost $1.1 million to the offering, demonstrating their dedication to the company’s expansion in the future.

Key Investors and Financial Impact

The private placement was directly executed without intermediaries such as placement agents, brokers, or underwriters. Velan Capital spearheaded the investment round, joined by prominent institutional investors including Nantahala Capital, Rubric Capital Management LP, Stonepine Capital Management, and Broadfin Holdings LLC. Existing shareholders and company insiders also participated in the transaction.

On February 12, 2025, the offering concluded successfully, bringing in around $15.0 million in gross revenues before offering-related costs were subtracted. According to Edesa, the net funds will mostly go toward advancing its CXCL10 monoclonal antibody, EB06, into a Phase 2 therapeutic study that targets vitiligo that is not segmented. The proceeds will also help with working capital requirements and other normal business expenditures.

Details of the Conversion and Governance Changes

Subject to modifications and exclusions, each Series B-1 Preferred Share has a stated value of $10,000 and can be converted into common shares at a conversion price of $1.92. A beneficial ownership restriction, which prevents any one investor from owning more than 4.99% of EDSA’s outstanding common shares, nonetheless limits conversion.

In conjunction with the private placement, Velan Capital’s Senior Analyst, David Liu, has been appointed to Edesa’s Board of Directors, effective immediately upon the transaction’s closure. This appointment aligns with the terms of an Investor Rights Agreement established as part of the offering.

Analyst Ratings and Peer Stock Comparison

EDSA holds a “Buy” rating from all seven analysts covering the stock, reinforcing strong market confidence in the biotechnology firm. Investors can explore similar or higher-rated stocks by visiting our ST screener link, where a comprehensive list of peer stocks is available for comparison.

Edesa Biotech, Inc. (NASDAQ: EDSA) witnessed a notable upsurge in its stock performance during the extended trading session on Thursday. The value of Edesa’s stock experienced a remarkable increase of 17.30%, reaching $4.00 in the after-hours trading period.

Prior to this, during the standard trading session, EDSA’s stock had already displayed a substantial rise of 6.56%, culminating at $3.41. This surge in EDSA’s stock price was instigated by the company’s active participation and presentation at a prestigious dermatology drug development summit.

The occasion which marked Edesa’s presence was the 7th Annual Dermatology Drug Development Summit. The Summit was held in Boston, Massachusetts, from October 31 to November 2, 2023. The keynote address was delivered by Dr. Par Nijhawan, Edesa’s Chief Executive Officer, who, among other salient topics, provided an insightful case study on the regulatory pathway pertaining to Edesa’s investigational drug EB06. This particular drug has shown promise as a potential remedy for individuals suffering from moderate to severe nonsegmental vitiligo.

Of note, Health Canada has granted approval to Edesa’s proposal to align the clinical trial designs between the United States and Canada for an ongoing Phase 3 study of EB05, also known as paridiprubart. Edesa’s monoclonal antibody is currently under evaluation as a prospective treatment for Acute Respiratory Distress Syndrome (ARDS).

The harmonized protocol for this study outlines the treatment of approximately 600 ARDS patients who are hospitalized and afflicted with SARS-CoV2 infections. These individuals are under invasive machine-assisted breathing, with or without supplementary help for their organs, like extracorporeal membrane oxygenation (ECMO).

The main concern of this research is the evaluation of death rates after 28 days. This modified research layout replaces the earlier plan, which aimed at a larger group of over 800 participants, with two distinct groups and specific goals for each group.

Earlier this year, Edesa made an agreement with the U.S. Food and Drug Administration to create a more streamlined approach, concentrating on a smaller population for the Phase 3 research. Edesa CEO mentioned that the adoption of a uniform and standardized plan in both the United States and Canada is expected to simplify the procedures for enrolling patients, managing trials, and analyzing data.